Literature DB >> 24297579

Outcomes of antiplatelet therapy for haemorrhage patients after thrombolysis: a prospective study based on susceptibility-weighted imaging.

Lei Yan1, Yong-Dong Li, Yue-Hua Li, Ming-Hua Li, Jun-Gong Zhao, Shi-Wen Chen.   

Abstract

PURPOSE: The authors evaluated the effect of susceptibility-weighted imaging (SWI) for antiplatelet therapy on post-thrombolysis microbleeds (MB).
MATERIALS AND METHODS: A total of 146 patients without symptomatic intracranial haemorrhage on computed tomography after thrombolysis were allocated to two groups: group A (n = 72) received antiplatelets 24 h after recombinant tissue plasminogen activator, regardless of SWI-detected haemorrhage; group B (n = 74) received antiplatelets for patients without SWI-visualised haemorrhage.
RESULTS: Haemorrhage was detected by SWI in 22 and 28 patients in groups A and B, respectively. The difference in mean NIHSS (National Institutes of Health Stroke Scale) score in group A between baseline and 6, 24 h, 7, 14 days was -1.6, -1.7, -3.6, -5.9, respectively; in group B, the difference in mean NIHSS score between baseline and 6, 24 h, 7, 14 days was -2.6, -3.3, -5.4, -8.7, respectively. The difference between groups in reduction of mean NIHSS score from baseline was 1.0 (p < 0.001) at 6 h, 1.6 (p < 0.001) at 24 h, 1.8 (p = 0.001) at 7 days and 2.8 (p < 0.001) at 14 days. NIHSS scores at 7, 14 days and modified Rankin scale at 90 days were significantly lower in haemorrhage patients in groups B than in A, whereas the hospital stay was shorter and the rate of favourable outcome at 90 days was higher.
CONCLUSION: Our results indicated that SWI was an effective approach for the guidance of antiplatelet therapy in post-thrombolysis MB.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24297579     DOI: 10.1007/s11547-013-0328-1

Source DB:  PubMed          Journal:  Radiol Med        ISSN: 0033-8362            Impact factor:   3.469


  27 in total

1.  Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism.

Authors:  A Furlan; R Higashida; L Wechsler; M Gent; H Rowley; C Kase; M Pessin; A Ahuja; F Callahan; W M Clark; F Silver; F Rivera
Journal:  JAMA       Date:  1999-12-01       Impact factor: 56.272

Review 2.  Magnetic resonance imaging criteria for thrombolysis in acute cerebral infarct.

Authors:  N Hjort; K Butcher; S M Davis; C S Kidwell; W J Koroshetz; J Röther; P D Schellinger; S Warach; L Østergaard
Journal:  Stroke       Date:  2004-12-23       Impact factor: 7.914

3.  Interobserver agreement for the assessment of handicap in stroke patients.

Authors:  J C van Swieten; P J Koudstaal; M C Visser; H J Schouten; J van Gijn
Journal:  Stroke       Date:  1988-05       Impact factor: 7.914

4.  Risk factors for severe hemorrhagic transformation in ischemic stroke patients treated with recombinant tissue plasminogen activator: a secondary analysis of the European-Australasian Acute Stroke Study (ECASS II).

Authors:  V Larrue; R von Kummer R; A Müller; E Bluhmki
Journal:  Stroke       Date:  2001-02       Impact factor: 7.914

5.  MRI screening before standard tissue plasminogen activator therapy is feasible and safe.

Authors:  Dong-Wha Kang; Julio A Chalela; William Dunn; Steven Warach
Journal:  Stroke       Date:  2005-08-04       Impact factor: 7.914

6.  Old microbleeds are a potential risk factor for cerebral bleeding after ischemic stroke: a gradient-echo T2*-weighted brain MRI study.

Authors:  N Nighoghossian; M Hermier; P Adeleine; K Blanc-Lasserre; L Derex; J Honnorat; F Philippeau; J F Dugor; J C Froment; P Trouillas
Journal:  Stroke       Date:  2002-03       Impact factor: 7.914

Review 7.  Susceptibility weighted imaging: a new tool in magnetic resonance imaging of stroke.

Authors:  K Santhosh; C Kesavadas; B Thomas; A K Gupta; K Thamburaj; T Raman Kapilamoorthy
Journal:  Clin Radiol       Date:  2008-08-21       Impact factor: 2.350

8.  Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke. The NINDS t-PA Stroke Study Group.

Authors: 
Journal:  Stroke       Date:  1997-11       Impact factor: 7.914

9.  Improved reliability of the NIH Stroke Scale using video training. NINDS TPA Stroke Study Group.

Authors:  P Lyden; T Brott; B Tilley; K M Welch; E J Mascha; S Levine; E C Haley; J Grotta; J Marler
Journal:  Stroke       Date:  1994-11       Impact factor: 7.914

10.  Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials.

Authors:  Werner Hacke; Geoffrey Donnan; Cesare Fieschi; Markku Kaste; Rüdiger von Kummer; Joseph P Broderick; Thomas Brott; Michael Frankel; James C Grotta; E Clarke Haley; Thomas Kwiatkowski; Steven R Levine; Chris Lewandowski; Mei Lu; Patrick Lyden; John R Marler; Suresh Patel; Barbara C Tilley; Gregory Albers; Erich Bluhmki; Manfred Wilhelm; Scott Hamilton
Journal:  Lancet       Date:  2004-03-06       Impact factor: 79.321

View more
  4 in total

Review 1.  Susceptibility-weighted imaging: current status and future directions.

Authors:  Saifeng Liu; Sagar Buch; Yongsheng Chen; Hyun-Seok Choi; Yongming Dai; Charbel Habib; Jiani Hu; Joon-Yong Jung; Yu Luo; David Utriainen; Meiyun Wang; Dongmei Wu; Shuang Xia; E Mark Haacke
Journal:  NMR Biomed       Date:  2016-05-18       Impact factor: 4.044

Review 2.  Effect of waivers of consent on recruitment in acute stroke trials: A systematic review.

Authors:  William B Feldman; Anthony S Kim; S Andrew Josephson; Daniel H Lowenstein; Winston Chiong
Journal:  Neurology       Date:  2016-03-23       Impact factor: 9.910

Review 3.  Antithrombotic treatment after stroke due to intracerebral haemorrhage.

Authors:  Luke A Perry; Eivind Berge; Joshua Bowditch; Elisabeth Forfang; Ole Morten Rønning; Graeme J Hankey; Elmer Villanueva; Rustam Al-Shahi Salman
Journal:  Cochrane Database Syst Rev       Date:  2017-05-25

Review 4.  Susceptibility-weighted Imaging in Thrombolytic Therapy of Acute Ischemic Stroke.

Authors:  Lin Li; Ming-Su Liu; Guang-Qin Li; Yang Zheng; Tong-Li Guo; Xin Kang; Mao-Ting Yuan
Journal:  Chin Med J (Engl)       Date:  2017-10-20       Impact factor: 2.628

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.